JPMorgan Chase & Co. resumed coverage on Abcam
$ABCM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JPMorgan Chase & Co. resumed coverage of Abcam with a rating of Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/20/2023 | $23.00 → $22.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 6/16/2023 | $25.00 | Neutral → Buy | BofA Securities |
| 12/14/2022 | $15.00 | Hold | Deutsche Bank |
15-12G - Abcam plc (0001492074) (Filer)
S-8 POS - Abcam plc (0001492074) (Filer)
S-8 POS - Abcam plc (0001492074) (Filer)
RBC Capital Mkts downgraded Abcam from Outperform to Sector Perform and set a new price target of $22.00 from $23.00 previously
BofA Securities upgraded Abcam from Neutral to Buy and set a new price target of $25.00
Deutsche Bank initiated coverage of Abcam with a rating of Hold and set a new price target of $15.00